Key Takeaways, With Data for Maryland FDA approvals vary by drug: There are currently three GLP-1s on the market that the FDA ...

Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.

The study followed nearly 17 million people, the majority of whom were in the 26-75 age range, and found that after climbing ...

Results of the study indicate that Black women in the U.S., ages 66-75, saw the largest decrease in obesity between 2022-2023 ...

Some people are not taking weight-loss medications responsibly, the physician says, and don't realize their full implications ...

The secret agent in the decrease might be semaglutide, a GLP-1 receptor agonist that fuels popular weight loss drugs like ...

When you think of a top weight loss drug, chances are that Ozempic is the name that first comes to mind. Although it is ...

Nestle is launching protein shots in the United States which it says help suppress appetite for people looking to shed pounds ...

Biden officials recently proposed allowing Medicare to start covering GLP-1 medications to treat obesity. It's unclear ...

Doctors might be slow to admit it, but Ozempic and other GLP-1 drugs are making dieting and exercise obsolete.

A few years ago, West Virginia, which has the highest obesity rate in the nation, quietly began a small and unusual pilot ...

MERCK snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as US$2 billion. Read ...